Person:
Marco Martínez, Fernando

Profile Picture
First Name
Fernando
Last Name
Marco Martínez
URI
https://hdl.handle.net/20.500.14352/79599
Affiliation
Universidad Complutense de Madrid
Faculty / Institute
Medicina
Department
Cirugía
Area
Traumatología y Ortopedia
Identifiers
UCM identifierScopus Author IDWeb of Science ResearcherIDDialnet ID

Filters

20192
Reset filters

Settings

Author: Abasolo, Lydia ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    RNA sequencing of mesenchymal stem cells reveals a blocking of differentiation and immunomodulatory activities under inflammatory conditions in rheumatoid arthritis patients
    (Arthritis Research & Therapy, 2019) Lamas, José Ramón; Fernández Gutiérrez, Benjamín; Mucientes, Arkaitz; Marco Martínez, Fernando; Lópiz Morales, María Yaiza; Jover Jover, Juan Ángel; Abasolo, Lydia; Rodríguez Rodríguez, Luis
    Introduction: Mesenchymal stem cells (MSCs) have the ability to differentiate into different types of cells of the mesenchymal lineage, such as osteocytes, chondrocytes, and adipocytes. It is also known that under inflammatory stimuli or in the appropriate experimental conditions, they can also act as regulators of inflammation. Thus, in addition to their regenerating potential, their interest has been extended to their possible use in cell therapy strategies for treatment of immune disorders. Objective: To analyze, by RNA-seq analysis, the transcriptome profiling of allogenic MSCs under RA lymphocyte activation. Methods: We identified the differentially expressed genes in bone marrow mesenchymal stem cells after exposure to an inflammatory environment. The transcriptome profiling was evaluated by means of the precise measurement of transcripts provided by the RNA-Seq technology. Results: Our results evidenced the existence of blocking of both regenerative (differentiation) and immunomodulatory phenotypes under inflammatory conditions characterized by an upregulation of genes involved in immune processes and a simultaneous downregulation of genes mainly involved in regenerative or cell differentiation functions. Conclusions: We conclude that the two main functions of MSCs (immunomodulation and differentiation) are blocked, at least while the inflammation is being resolved. Inflammation, at least partially mediated by gamma-interferon, drives MSCs to a cellular distress adopting a defensive state. This knowledge could be of particular interest in cases where the damage to be repaired has an important immune-mediated component.
  • Thumbnail Image
    Item
    Check-control of inflammation displayed by bone marrow mesenchymal stem cells in rheumatoid arthritis patients
    (Immunotherapy, 2019) Lamas, José Ramón; Mucientes, Arkaitz; Lajas Petisco, Cristina De Jesús; Fernández Gutiérrez, Benjamín; Lópiz Morales, María Yaiza; Marco Martínez, Fernando; Jover Jover, Juan Ángel; Abasolo, Lydia; Rodríguez Rodríguez, Luis
    Background: Mesenchymal stem cells (MSCs) are a promising treatment of different musculoskeletal diseases including osteoarthritis and rheumatoid arthritis (RA). Results from different approaches in this treatment have been not conclusive. Aim: To analyze factors related to interactions between peripheral blood mononuclear cells (PBMCs) and MSCs and the influence of cellular activation. Materials & methods: PBMCs from RA patients and healthy controls (HC) were obtained. MSCs from bone marrow (BM-MSCs) were obtained from six donors. CD4, CD25, CD69 and CD127 expression was measured by flow cytometry. Repeated measures analysis of variance (ANOVA) models were performed using activation, co-culture with BM-MSCs and time of culture (24 h, 72 h, 6 days) as within-subject variables. Results: PBMCs activated and co-cultured with BM-MSCs showed a lower proportion of CD25-positive and CD25high/CD127low-negative cells in both RA and HC. Additionally, a maintained expression of CD69 was also observed in RA and HC when PBMCs were activated and co-cultured with BM-MSCs. Conclusion: Both PBMC activation grade and RA disease activity influence the immunomodulatory effect of BM-MSCs on T-cell activation.